TABLE 1.
Demographic and clinical characteristics of the patients.
| Patients | Onset age, y | Sex | Seizure type | Seizure frequency | Duration, m |
Initial AED | Maintenance Dose, mg | Seizure controlled | |
| Enrollment | Follow-up | ||||||||
| 1 | 6.95 | F | FS with PA | Four episodes | 8.9 | 22.6 | LEV | 1000 | Y |
| 2 | 4.64 | M | Focal to bilateral TCS | Three episodes | 9.7 | 22.9 | VPA | 750 | N |
| 3 | 7.93 | F | Focal to bilateral TCS | Weekly | 4.6 | 15.8 | LEV | 1750 | N |
| 4 | 4.43 | M | FS with IA | Four episodes | 10.9 | 20.3 | LEV | 750 | Y |
| 5 | 9.65 | F | Focal to bilateral TCS | One episode | 5.6 | 14.7 | LEV | 750 | N |
| 6 | 9.46 | M | Focal to bilateral TCS | Two episodes | 6.1 | 24.4 | LEV | 1000 | N |
| 7 | 8.89 | M | Focal to bilateral TCS | Three episodes | 0.5 | 9.3 | OXC | 450 | Y |
| 8 | 8.25 | F | FS with PA | Two episodes | 5.7 | 16.5 | OXC | 600 | N |
| 9 | 7.23 | F | FS with IA | Two episodes | 9.5 | 25.1 | LEV | 1250 | N |
| 10 | 9.60 | F | FS with IA | Three episodes | 7.7 | 16.6 | OXC | 750 | N |
| 11 | 7.18 | M | Focal to bilateral TCS | Two episodes | 1.3 | 11.9 | VPA | 500 | Y |
| 12 | 8.93 | M | FS with PA | Four episodes | 14.5 | 28.7 | LEV | 1500 | Y |
| 13 | 5.15 | F | FS with IA | Four episodes | 4.5 | 15.5 | OXC | 450 | Y |
| 14 | 7.30 | F | FS with PA | Two episodes | 0.8 | 13.4 | LEV | 1000 | Y |
| 15 | 6.21 | M | Focal to bilateral TCS | Three episodes | 5.7 | 17.3 | OXC | 600 | N |
F, female; M, male; FS, focal seizures; PA, preserved awareness; IA, impaired awareness; TCS, tonic-clonic seizures; AED, antiepileptic drug; LEV, levetiracetam; VPA, valproic acid; OXC, oxcarbazepine; Y, yes; N, no.